RT Journal Article
T1 Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
A1 Santos González, Jesús L
A1 Palacios Muñoz, Rosario
A1 Lozano, Fernando
A1 López, Manuel
A1 Gálvez, María Carmen
A1 de las Torres, Javier
A1 López-Cortés, Luis Fernando
A1 Ríos, María José
A1 Rivero Román, Antonio
K1 Benzoxazinas
K1 Lamivudine
K1 Efavirenz
K1 Didanosina
K1 Fármacos Anti-VIH
K1 Quimioterapia Combinada
K1 Estudios de Seguimiento
K1 Humanos
K1 Adulto
K1 Infecciones por VIH
K1 VIH-1
K1 Carga Viral
K1 Inhibidores de Transcriptasa Inversa
K1 Resultado del Tratamiento
AB The aim of this study was to evaluate the long-term efficacy and safety of didadosine (ddI), lamivudine (3TC), and efavirenz (EFV). This was a follow-up to the VESD study, a 12-month open-label, observational, multicenter study of adult patients with HIV infection who started antiretroviral treatment with the ddI-3TC-EFV once-daily regimen. Of the 167 patients originally included, 106 patients remained on the same triple therapy at the end of the study (1 year), and they were offered an extra 24 months of follow-up; 96 were enrolled in this study (VESD-2). Seventy patients out of the initial cohort were still on the same regimen at month 36, with 97% of them with plasma viral load <50 copies /ml. An intention-to-treat analysis showed that the percentage of patients with plasma viral load <50 copies/ml was 73% at 36 months. CD4 cell counts increased 344 cells/microl over the 36 months. Safety and tolerance were good with no unexpected long-term toxicity. After 3 years of treatment with ddI-3TC-EFV, more than 40% of the patients were still receiving the initial antiretroviral therapy with sustained, durable immunovirological benefit and good acceptance. Long-term toxicity and virological failure were low.
PB Mary Ann Liebert
YR 2008
FD 2008-01-15
LK http://hdl.handle.net/10668/834
UL http://hdl.handle.net/10668/834
LA en
NO Santos J, Palacios R, Lozano F, López M, Gálvez MC, de la Torres J, et al. Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up. AIDS Res. Hum. Retroviruses. 2008                         ; 24(1):24-6
NO Clinical Trial; Journal Article; Multicenter Study;
DS RISalud
RD Apr 7, 2025